General Prognostics

General Prognostics (GPx) is revolutionizing remote chronic disease management with the world's first bloodless blood tests.

  • Stage Product In Development
  • Industry Healthcare Services
  • Location Boston, MA, USA
  • Currency USD
  • Founded April 2020
  • Employees 12
  • Incorporation Type C-corp
  • Website gpx.ai

Company Summary

GPx is pioneering Bloodless Blood Tests by leveraging AI to calibrate digital biomarkers with blood biomarkers and delivering clinically actionable information about patient status on a timely/cost-effective basis. As GPx collects patient data to enhance the algorithm, the blood test will be eliminated to achieve a fully digital bloodless blood test.

Team

  • Sean Matsuoka
    COO/Co-Founder

    Sean Matsuoka leads BD and fundraising . Experience in Marketing at Sony Corporation, McKinsey & Co., Sales/BD at {caresyntax & M3 Inc. BA in Law from Keio University, MBA from Harvard Business School.

  • Javier Echenique
    CEO/Co-Founder

    Javier leads product, KOL partnerships, and clinical functions. He has experience in engineering, sales, and product management from Medtronic, HeartWare, and Volcano. He led patient management efforts at HeartWare and launched multiple patient diagnostic products including the company’s remote monitoring platform. BS/MS in Mechanical Engineering from MIT, MBA from Harvard Business School.

Advisors

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free